Acyte Biotech capitalises on tiny microbes
21 February, 2002 by Daniella GoldbergTwo major multinational pharmaceutical companies and two ASX-listed biotechs are vying for the a new biopharmaceutical platform technology developed by Acyte Biotech, a spin-off company from the University of New South Wales.
Hong Kong destined for best supporting role in biotech
21 February, 2002 by Chee Sing ChanAnalysts and industry experts are widely predicting biotechnology and life sciences to be strong growth areas this year, but in comparison to other Asian markets, Hong Kong seems off the pace.
CSL looks to the US after solid half-year result
21 February, 2002 by Tanya HollisBlood products and vaccine manufacturer CSL has announced it more than doubled its interim profit to $57.5 million on the back of its acquisition of Swiss plasma supplier ZLB last year.
Cochlear bucks uncertainty, meets expectations
21 February, 2002 by Daniella GoldbergCochlear shares gained $A3.90 (+10.1 per cent) to close at $A42.50 on February 18 after half-yearly reports for the six months ended 31 December 2001 showed that the company would meet its long-term growth target of 20 per cent a year.
Ambri prepares its first instrument for market
21 February, 2002 by Daniella GoldbergSydney-based nanotechnology company Ambri Limited is on track to deliver its first biosensor to the Australian market in June, after hooking up with local instrument manufacturer Vision Biosystems.
Florigene gets the Tasmanian blues
21 February, 2002 by Tanya HollisBlue carnations won't be appearing in Tasmanian gardens, after a Melbourne molecular breeder vowed it "would not waste its time" trying to have a GMO ban in the state overturned.
Spirits up at Amrad despite revenue slide
20 February, 2002 by Tanya HollisA promising development pipeline is keeping spirits high at Amrad Corporation despite its posting a $54.6 million drop in revenues in the last half of 2001.
GE free? Don't tell us about it, says Qld govt
20 February, 2002 by Pete YoungVoluntary bans by local farmers are a preferable way of creating GM crop-free areas than passing State laws, says Queensland Premier Peter Beattie.
Interim loss, but EpiTan still in the sun
20 February, 2002 by Tanya HollisThe Melbourne company behind a tanning drug has posted a $1.5 million interim loss as it pushes towards advanced human trials.
IBM, Accelrys join hands to boost drug development
20 February, 2002 by Sumner LemonIBM and software developer Accelrys have announced an alliance aimed at developing collaborative applications that will help pharmaceutical companies shorten the development cycles for new drugs.
Clone company bullish in Asian market
18 February, 2002 by Melissa TrudingerTwo cloned calves of a top breeding bull are being sold in Asia by Australian breeder RAB for almost $400,000 each.
Microbes cop a double whammy with new drug
18 February, 2002 by Melissa TrudingerPerth biotech Chemeq Ltd (ASX: CMQ) has developed a new kind of antimicrobial that may revolutionise agriculture and reduce the development of drug-resistant bacteria.
GM antibody technology a shot in the arm for Agen
18 February, 2002 by Pete YoungAgen Biomedical is putting an improved version of its 20-year-old cash cow out to graze in fresh pastures.
New drug chews the fat for Metabolic
18 February, 2002 by Melissa TrudingerMelbourne-based Metabolic Pharmaceuticals is claiming early phase clinical trial success with its new obesity drug.
Our clones are safe, says company
18 February, 2002 by Melissa TrudingerMelbourne-based biotech Clone International has distanced itself from a new Japanese study that casts doubt on the safety and usefulness of a cloning technique.
